HAVCR2 and neoplasm: The molecular mechanism of TIM3-mediated immune regulation in DCs remains to be explored in the future: (1) Deciphering ligand selectivity and the downstream signaling pathways underlying the immune-activating effects of TIM3 in DCs; (2) Investigating the molecular crosstalk between TIM3 and antigen presentation machinery to delineate its regulatory mechanisms; (3) Exploring combinatorial strategies with other immune checkpoints to develop synergistic immunotherapies that overcome tumor-mediated immunosuppression.